|
|
|
2009 Neurotech Leaders Forum
and NeuroInvestment Conference
October 26-27, 2009
Radisson Hotel, Newport Beach, CA
Tentative Agenda
Day One: Technology Basics
The first day of the 2009 event is devoted to basic information about the neurotechnology and neuropharmaceutical industries, targeted at early-stage neurotech and pharma firms and research professionals contemplating launching a start-up. Conference faculty will offer a detailed background on the basics of both neurotechnolgy devices and neuropharmaceuticals. The afternoon offers a valuable session on obtaining financing and concludes with a panel discussion of issues affecting end users in the neurological disorders community.
| 8:00-8:30 |
Registration and Coffee |
| 8:30-10:00 |
Basic Neurotechnology Principles
Warren Grill, Ph.D., Senior Technical Editor, Neurotech Reports
In this session, one of the nation's leading experts on neurotechnology, Warren Grill of Duke University, will present a tutorial on the fundamentals of neurostimulation, neuromodulation, deep-brain stimulation, and related topics. The tutorial will explain how neurotech devices work, and include a discussion of product features, stimulation parameters, targeted locations. |
Current State-of-the-Art for NeuroPharm
Harry Tracy, Ph.D., Editor, NeuroInvestment
This session will provide a pointed look at the current status of pharma and cell therapeutics in development for neurological and psychiatric disorders. It will provide a critical overview of the disorders, the opportunities, and the progress, or lack thereof, achieved thus far. |
| 10:00-10:30 |
Refreshment Break |
| 10:30-12:00 |
Neurotechnology Market Overview
James Cavuoto, Editor and Publisher, Neurotech Reports
This session gives attendees an overview of the neurotechnology device market, with discussion of overall size, market segments, growth rates, competition, and key players. It will also include discussion of the various markets for neurological diseases and disorders. |
Ten Unanswered Questions Facing Neuropharm and Cell Therapies
Harry Tracy, Ph.D., Editor, NeuroInvestment
This session will consider some of the crucial questions whose answers will either determine what paths will be successful, or will illuminate the way to those paths more effectively than is currently possible. The questions include: Do we have the right targets, and if not, why not? Proteins vs. small molecules: is size or specificity more important? When will NCE’s become better investments than molecules-in-rehab? Can we get the FDA to forget they ever heard of the ADAS-cog? |
| 12:00-1:30 |
Luncheon, Sponsored by Quallion, LLC
Luncheon Speaker, Paul Beach, Quallion, LLC., Vice-President of Business Development, Quallion LLC |
| 1:30-3:00 |
Obtaining Venture Capital Financing
Glenn Cornett, Ph.D., M.D., Senior Financial Editor, Neurotech Reports
This session offers specific and practical advice on preparing a set of initial materials, including executive summary, investor presentation, and financial model, that will attract attention from venture capital firms. It includes examples of items that have made the difference between funding and no funding decisions. The presenter will also discuss how to find the most appropriate VC firm and how to arrange a meeting with the key person at the firm. |
| 3:00-3:15 |
Refreshment Break |
| 3:15-4:00 |
Neurological Disorders Panel
James Cavuoto, Editor and Publisher, Neurotech Reports
Harry Tracy, Ph.D., Editor, NeuroInvestment
Warren Grill, Ph.D., Senior Technical Editor, Neurotech Reports
Glenn Cornett, Ph.D., M.D., Senior Financial Editor, Neurotech Reports
In this interactive panel discussion, Neurotech Leaders Forum faculty will examine each category of neurological diseases and disorders and offer their insight on the current and future competitive landscape for both drug and device therapies. Disorder categories include movement disorders, neurodegenerative disorders, psychiatric disorders, brain and spinal cord injuries, stroke, epilepsy, and pain. |
| 4:00-5:00 |
Clinician/Consumer Panel
Jennifer French, Executive Director, Neurotech Network, Moderator
Roy Simon, M.D., Pain and Rehabilitation Medical Group
Greg Thompson, Chief of Social Work, Rancho Los Amigos National Rehabilitation Center
Nan Luke, National Multiple Sclerosis Society
This panel will bring together practicing clinicians and users of neurotechnology products. Discussion topics will be directed at the barriers of acceptance for neurotechnology in clinical practice. Such topics will include concerns of safety and compliance to the patient, financial access, and technology education. |
| 5:00-7:00 |
Cocktail Reception
|
| |
|
Day Two: Industry Issues
The second day of the conference offers an exclusive forum for neurotechnology and neuropharmaceutical executives and entrepreneurs to interact with investors, technologists, and potential partners who are working to grow this new industry.
| 8:00-8:30 |
Registration and Coffee |
| 8:30-8:45 |
Introductions |
| 8:45-9:15 |
Neurotechnology Industry Update
James Cavuoto, Editor and Publisher, Neurotech Reports
This session will provide attendees with an up-to-date look at the neurotechnology industry, including discussion of deals, merger and acquisition activity, and venture capital funding that has occurred in the last year. |
| 9:15-10:00 |
Regulatory/Reimbursement Update
Harry Tracy, Ph.D., Editor, NeuroInvestment
Gerald Rogan, M.D., Principal, Rogan Consulting
This session offers an inportant update on the likely impact of health care reform on neurotechnology device and neuropharmaceutical manufacturers. The session will look at changes in Medicare reimbursement rates and new FDA aftermarket review procedures. |
| 10:00-10:30 |
Coffee Break
|
| 10:30-11:15 |
Advances in Neurostimulator Design
James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Rob Sjostedt, President and CEO, Bal Seal Engineering
Joe Schulman, Ph.D., President Emeritus, Alfred Mann Foundation
Paul Beach, J.D., Vice-President of Business Operations, Quallion LLC
This session will highlight new trends and techniques in the design of neurostimulation devices. Topics to be covered include miniaturization, new batteries, new electrode configurations, programmers, and novel waveforms.
|
Neuropharm Panel Discussion I: 10 Challenges for the Industry
Harry Tracy , Ph.D, Editor, NeuroInvestment, Moderator
Chris Fibiger, CSO, Biovail
Chris Gallen M.D., Ph.D., CEO, CombinatoRx/Neuromed
Gerhard Koenig, Ph.D., CSO, EnVivo Pharmaceuticals
Ten Challenges for the industry, and some potential solutions, will be discussed by the members of this panel. |
| 11:15-12:00 |
Closing the Loop with Neurosensing
Jennifer French, Executive Director, Neurotech Network, Moderator
Philip Kennedy, M.D., Ph.D., President and CEO, Neural Signals Inc.
George Carpenter, CEO, CNS Response Inc.
Daniel Chao, M.D., Director of Business Development, NeuroPace Inc.
This session examines the critical role that neurosensing devices can play, both as stand-alone diagnostic systems and as components in an intelligent neuroprosthetic or neuromodulation system. |
Neuropharm Panel Discussion II: The Independent CNS Company
Harry Tracy, Ph.D., Editor, NeuroInvestment, Moderator
Chris Fibiger, CSO, Biovail
Jim Schoeneck, CEO, BrainCells
Gordon McCauley, CEO, Allon Therapeutics
In this session, panelists will discuss the independent CNS company path forward: Is there still a way to survive and prosper? |
| 12:00-1:30 |
Luncheon
Presentation of 2009 Gold Electrode Awards |
| 1:30-3:15 |
Entrepreneur Panel
James Cavuoto, Editor, Neurotech Reports, Moderator
Will Rosellini, CEO, MicroTransponder Inc.
Gerhard Koenig, Ph.D., CSO, EnVivo Pharmaceuticals, Inc.
Steven Stupp, Ph.D., CEO, TriGeminal Solutions
Paul Meadows, CTO, ImThera Medical Inc
William Comer, Ph.D., CEO, Neurogenetic Pharmaceuticals
Ben Matteo, CEO, EOS Neuroscience
David Campbell, Ph.D., CSO, Afraxis
This session features presentations from CEOs and executives of several neurotechnology and neuropharmaceutical start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
| 3:15-3:30 |
Refreshment Break |
| 3:30-4:15 |
Neurotech and Neuropharma Failures: What Went Wrong?
James Cavuoto, Editor, Neurotech Reports
Harry Tracy, Ph.D., Editor, NeuroInvestment
In this unique session, James Cavuoto and Harry Tracy, editors of the two most influential industry newsletters in the neuro space, offer their frank analysis of noteworthy failures from the neurotech device and neuropharmaceutical industries. The pair will share stories of failed trials, mergers, and product launches and discuss their impact on future products. |
| 4:15-5:00 |
Investment Panel
James Cavuoto, Editor, Neurotech Reports, Moderator
Daniel O'Connell, Managing Partner, NeuroVentures
Andy Jane, Partner, CM Capital
Rob Abrams, Operating Principal, Sanderling Ventures
Stephanie Fertig, Small Business Program Coordinator, NIH/NINDS
In this wrap-up session, representatives from several key venture capital firms in the life sciences space will offer their feedback on the status of the neurotechnology and neuropharmaceutical industries and their impressions of the issues discussed during the day. |
| 5:00-7:00 |
Cocktail Reception |
| |
|
|
